Sort   by:  
 Page size 
UnknownNeutralising antibody potency against SARS-CoV-2 wild-type and omicron BA.1 and BA.4/5 variants in patients with inflammatory bowel disease treated with infliximab and vedolizumab after three doses of COVID-19 vaccine (CLARITY IBD): an analysis of a prospective multicentre cohort study.
Not available
S-EPMC9757903 | biostudies-literature
UnknownStratified analyses refine association between TLR7 rare variants and severe COVID-19.
Not available
S-EPMC11320601 | biostudies-literature
UnknownAdd-On Treatment With Zilebesiran for Inadequately Controlled Hypertension: The KARDIA-2 Randomized Clinical Trial.
Not available
S-EPMC12120674 | biostudies-literature
UnknownThe effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial.
Not available
S-EPMC3145073 | biostudies-literature
UnknownGWAS and meta-analysis identifies 49 genetic variants underlying critical COVID-19.
Not available
S-EPMC10208981 | biostudies-literature
UnknownWhole-genome sequencing reveals host factors underlying critical COVID-19.
Not available
S-EPMC9259496 | biostudies-literature
UnknownCommon, low-frequency, rare, and ultra-rare coding variants contribute to COVID-19 severity.
Not available
S-EPMC8661833 | biostudies-literature
UnknownA second update on mapping the human genetic architecture of COVID-19.
Not available
S-EPMC10482689 | biostudies-literature
UnknownEmpagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC10957483 | biostudies-literature
UnknownHigher dose corticosteroids in hospitalised COVID-19 patients requiring ventilatory support (RECOVERY): a randomised, controlled, open-label, platform trial.
Not available
S-EPMC11872607 | biostudies-literature
Sort   by:  
 Page size